PGRP-LB reduces pathway activity by degrading free peptidoglycan—that is, it reduces pathway activity only when the immune response has been effective in killing bacteria; it was thus particularly interesting because its activation upon infection renders the IMD pathway responsive to its own success. The gene discussed is PGLYRP1; the disease is infection.